ArticleParasites & vectors2015
What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection?
Article in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Factors affecting the uptake of preventive chemotherapy treatment for schistosomiasis in Sub-Saharan Africa: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- The epidemiology and chemotherapeutic approaches to the control of urinary schistosomiasis in school-age children (SAC): a systematic review.BMC infectious diseases · 2019Pooled it
- Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review.Parasites & vectors · 2016Pooled it
- Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- SCORE Operational Research on Moving toward Interruption of Schistosomiasis Transmission.The American journal of tropical medicine and hygiene · 2020Trial
- Impact of Different Mass Drug Administration Strategies for Gaining and Sustaining Control ofThe American journal of tropical medicine and hygiene · 2020Trial
- Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: A SCORE project in Northern Mozambique.PLoS neglected tropical diseases · 2017Trial
- How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis.PLoS neglected tropical diseases · 2025Article
- National Consensus on Introducing and Delivery of Paediatric Praziquantel for Curative and Preventive Treatment of Schistosomiasis Among Pre-school Children in Tanzania.The East African health research journal · 2025Article
- Revisiting immunity vs. exposure in schistosomiasis: A mathematical modeling study of delayed concomitant immunity.PNAS nexus · 2024Article
- Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Subtle transcriptomic response of Eurasian perch (International journal for parasitology. Parasites and wildlife · 2023Article
- Precision mapping of schistosomiasis and soil-transmitted helminthiasis among school age children at the coastal region, Kenya.PLoS neglected tropical diseases · 2023Article
- What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?PLoS neglected tropical diseases · 2021Article
- Schistosomiasis in Nigeria: Gleaning from the past to improve current efforts towards control.One health (Amsterdam, Netherlands) · 2020Review
- Defining a prevalence level to describe the elimination of Lymphatic Filariasis (LF) transmission and designing monitoring & evaluating (M&E) programmes post the cessation of mass drug administration (MDA).PLoS neglected tropical diseases · 2020Article
- Application of Schistosomiasis Consortium for Operational Research and Evaluation Study Findings to Refine Predictive Modeling ofThe American journal of tropical medicine and hygiene · 2020Review
- Parasite Population Genetic Contributions to the Schistosomiasis Consortium for Operational Research and Evaluation within Sub-Saharan Africa.The American journal of tropical medicine and hygiene · 2020Review
- Impact of Different Sampling Schemes for Decision Making in Soil-Transmitted Helminthiasis Control Programs.The Journal of infectious diseases · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchistosomiasis is endemic in 54 countries, but has one of the lowest coverages by mass drug administration of all helminth diseases. However, with increasing drug availability through donation, the World Health Organisation has set a goal of increasing coverage to 75 % of at-risk children in endemic countries and elimination in some regions. In this paper, we assess the impact on schistosomiasis of the WHO goals in terms of control and elimination.
methodsWe use an age-structured deterministic model of schistosome transmission in a human community and the effect of mass drug administration. The model is fitted to baseline data from a longitudinal re-infection study in Kenya and validated against the subsequent re-infection data. We examine the impact on host worm burden of the current treatment trend, extrapolated to meet the WHO goals, and its sensitivity to uncertainty in important parameters. We assess the feasibility of achieving elimination.
resultsModel results show that the current treatment trend, extrapolated to the WHO goals, is able to greatly reduce host worm burdens. If coverage is continued at the same level beyond 2020, elimination is possible for low to moderate transmission settings, where transmission intensity is defined by the basic reproduction number, R0. Low levels of adult coverage have a significant impact on worm burden in all settings. Model validation against the re-infection survey demonstrates that the age-structured model is able to match post-treatment data well in terms of egg output, but that some details of re-infection among school children and young adults are not currently well represented.
conclusionsOur work suggests that the current WHO treatment goals should be successful in bringing about a major reduction in schistosome infection in treated communities. If continued over a 15 year period, they are likely to result in elimination, at least in areas with lower transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.